TRAF6 Is Over-Expressed in Multiple Myeloma and Blocking Its Intracellular Signaling Shows Both Anti-Tumor and Anti-Bone Resorptive Effects

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR.

Abstract

Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK signaling pathways. Here, TRAF6 protein was determined to be overexpressed in bone marrow mononuclear cells (BMMCs) from multiple myeloma (MM) patients. TRAF6 expression in BMMCs from patients with progressive disease is significantly elevated as compared to individuals in complete remission, with monoclonal gammopathy of undetermined significance, or healthy subjects. Furthermore, TRAF6 dominant negative (TRAF6dn) peptides were constructed which specifically reduced TRAF6 signaling and activation of IKK. TRAF6dn not only reduced cellular growth but increased the apoptosis of MM tumor cells in a concentration dependent fashion. Since TRAF6 activates IKK through polyubiquitination, independent of its proteasome activity, a TRAF6dn peptide was combined with the proteasome inhibitors bortezomib or carfilzomib to treat MM. Importantly, targeting of TRAF6 in the presence of proteasome inhibition enhanced anti-MM effects and also decreased TLR/TRAF6/NF-kappaB-related signaling. Finally, TRAF6dn dose-dependently inhibited osteoclast cell formation from CD14+ monocytes, induced with RANKL and mCSF, and markedly reduced bone resorption in dentin pits. In all, these data demonstrate that blocking TRAF6 signaling has anti-MM effects and reduces bone loss.

IMPLICATIONS: The ability to target TRAF6 signaling and associated pathways in multiple myeloma suggests a promising new therapeutic approach.